CN106176806A - A kind of Kanamycin sulfate eye drops and preparation method thereof - Google Patents

A kind of Kanamycin sulfate eye drops and preparation method thereof Download PDF

Info

Publication number
CN106176806A
CN106176806A CN201610744774.4A CN201610744774A CN106176806A CN 106176806 A CN106176806 A CN 106176806A CN 201610744774 A CN201610744774 A CN 201610744774A CN 106176806 A CN106176806 A CN 106176806A
Authority
CN
China
Prior art keywords
kanamycin sulfate
test tube
gram
grams
eye drops
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201610744774.4A
Other languages
Chinese (zh)
Inventor
葛长城
王殿阔
吴磊
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Anhui Aikeer Pharmaceutical Co Ltd
Original Assignee
Anhui Aikeer Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Anhui Aikeer Pharmaceutical Co Ltd filed Critical Anhui Aikeer Pharmaceutical Co Ltd
Priority to CN201610744774.4A priority Critical patent/CN106176806A/en
Publication of CN106176806A publication Critical patent/CN106176806A/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4415—Pyridoxine, i.e. Vitamin B6
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
    • A61K31/728—Hyaluronic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/14—Alkali metal chlorides; Alkaline earth metal chlorides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/22—Boron compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183—Amino acids, e.g. glycine, EDTA or aspartame
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Abstract

The invention discloses a kind of Kanamycin sulfate eye drops; its raw material is as follows: kanamycin sulfate 46 grams; vitamin B6 0.3 0.5 grams; sodium hyaluronate 23 grams; taurine 1 1.5 grams, 0.8 1 grams of sodium chloride, boric acid 0.2 0.4 grams; disodiumedetate 0.3 0.5 grams, distilled water 80 100 milliliters.A kind of Kanamycin sulfate eye drops that the present invention provides and preparation method thereof, by the addition of kanamycin sulfate, plurality of raw materials is mixed by the hybrid mode simultaneously using branch's formula so that mixed effect is more preferably applicable to treat conjunctivitis, keratitis, dacryocystisis, blepharitis, meibomitis etc. caused by the antibacterials such as sensitive escherichia coli, Klebsiella, Proteus, Diplococcus gonorrhoeae and staphylococcus to be infected.

Description

A kind of Kanamycin sulfate eye drops and preparation method thereof
Technical field
The present invention relates to eye drop technical field, particularly relate to a kind of Kanamycin sulfate eye drops and preparation method thereof.
Background technology
Collyrium is the liquid medicine for the treatment of disease of eye, and its composition has numerous species according to the difference of effect, such as steroid, anti- Raw element, antihistaminic, beta-blocker, non-steroidal anti-inflammatory analgesic etc..Kanamycin is a kind of aminoglycoside antibiotics. To most enterobacteriaceae lactobacteriaceaes, such as escherichia coli, Klebsiella, Proteus, Enterobacter, Shigella, sramana Pseudomonas, citrobacter genus, Pu Luofeideng Pseudomonas, yersinia's genus etc. all have good action；Hemophilus influenza, Brucella, brain Meningococcus, gonococcus etc. are also the most sensitive to this product, invalid to Pseudomonas aeruginosa.Quick to methicillin in staphylococcus Sense strain and mycobacterium tuberculosis also have certain effect, other gram-positive bacterias such as Hemolytic streptococcus, streptococcus pneumoniae, intestinal ball Bacterium and anaerobe etc. are to this product majority drug resistance.Kanamycin is mainly combined with bacterial ribosome 30S subunit, suppresses bacterioprotein The synthesis of matter.Kanamycin and streptomycin, neomycin have complete intersection drug resistance, partial intersection can be had resistance to other aminoglycosides Medicine.Kanamycin sulfate eye drops, indication for be applicable to treat sensitive escherichia coli, Klebsiella, Proteus, Conjunctivitis, keratitis, dacryocystisis, blepharitis, meibomitis etc. caused by the antibacterial such as Diplococcus gonorrhoeae and staphylococcus infect.
Summary of the invention
The invention aims to solve shortcoming present in prior art, and a kind of kanamycin sulfate proposed drips Ocular fluid and preparation method thereof.
To achieve these goals, present invention employs following technical scheme:
A kind of Kanamycin sulfate eye drops, its raw material is as follows: kanamycin sulfate 4-6 gram, vitamin B6 0.3- 0.5 gram, sodium hyaluronate 2-3 gram, taurine 1-1.5 gram, 0.8-1 gram of sodium chloride, boric acid 0.2-0.4 gram, ethylenediaminetetraacetic acid Disodium 0.3-0.5 gram, distilled water 80-100 milliliter.
Preferably, what described sodium hyaluronate used receives for powder clear matter acid, and powder mesh number is 1000 mesh.
The preparation method of a kind of Kanamycin sulfate eye drops, comprises the steps:
S1: prepare the test tube of two cleaning steriles, joined by kanamycin sulfate in test tube, falls the distilled water of half simultaneously Enter in test tube, firmly rock so that kanamycin sulfate is sufficiently mixed with distilled water, test tube is placed and water uses water-bath add The mode of heat heats, and bath temperature controls between 45-55 degree Celsius；
S2: by vitamin B6, sodium hyaluronate, taurine, sodium chloride, boric acid, disodiumedetate and second half steaming The test tube that distilled water is put in another test tube in mixing and stirring, with S1 heating in water bath in the same apparatus, it is ensured that two Test tube bath temperature is identical；
S3: solution in two test tubes is mixed, fully rocks so that solution mix homogeneously；
S4: sterilization treatment, uses the mode of high-temp steam sterilizing, is put into by mix reagent in high-temperature steam cabinet and carry out at sterilizing Reason；
S5: the solution through sterilization treatment is carried out filtration treatment, by Impurity removal, the drainage screen aperture of defecator is 1000 Mesh；
S6: by through filtration after solution subpackage in the vial, can use, subpackage in the vial time need bottleneck is gone out Bacterium processes.
A kind of Kanamycin sulfate eye drops that the present invention provides and preparation method thereof, adding by kanamycin sulfate Enter, use the hybrid mode of branch's formula plurality of raw materials to be mixed simultaneously so that mixed effect is more preferably applicable to treat sensitive large intestine Conjunctivitis, keratitis, tear caused by the antibacterials such as angstrom uncommon bacterium, Klebsiella, Proteus, Diplococcus gonorrhoeae and staphylococcus Capsulitis, blepharitis, meibomitis etc. infect.
Detailed description of the invention
In order to make the purpose of the present invention, technical scheme and advantage clearer, below in conjunction with specific embodiment, to this Invention is further elaborated.Should be appreciated that specific embodiment described herein only in order to explain the present invention, not For limiting the present invention.
Embodiment 1
A kind of Kanamycin sulfate eye drops, its raw material is as follows: kanamycin sulfate 4 grams, vitamin B6 0.3 gram, Sodium hyaluronate 2 grams, taurine 1 gram, 0.8 gram of sodium chloride, boric acid 0.2 gram, disodiumedetate 0.3 gram, distilled water 80 Milliliter.
What described sodium hyaluronate used receives for powder clear matter acid, and powder mesh number is 1000 mesh.
The preparation method of a kind of Kanamycin sulfate eye drops, comprises the steps:
S1: prepare the test tube of two cleaning steriles, joined by kanamycin sulfate in test tube, falls the distilled water of half simultaneously Enter in test tube, firmly rock so that kanamycin sulfate is sufficiently mixed with distilled water, test tube is placed and water uses water-bath add The mode of heat heats, and bath temperature controls between 45-55 degree Celsius；
S2: by vitamin B6, sodium hyaluronate, taurine, sodium chloride, boric acid, disodiumedetate and second half steaming The test tube that distilled water is put in another test tube in mixing and stirring, with S1 heating in water bath in the same apparatus, it is ensured that two Test tube bath temperature is identical；
S3: solution in two test tubes is mixed, fully rocks so that solution mix homogeneously；
S4: sterilization treatment, uses the mode of high-temp steam sterilizing, is put into by mix reagent in high-temperature steam cabinet and carry out at sterilizing Reason；
S5: the solution through sterilization treatment is carried out filtration treatment, by Impurity removal, the drainage screen aperture of defecator is 1000 Mesh；
S6: by through filtration after solution subpackage in the vial, can use, subpackage in the vial time need bottleneck is gone out Bacterium processes.
Embodiment 2
A kind of Kanamycin sulfate eye drops, its raw material is as follows: kanamycin sulfate 5 grams, vitamin B6 0.4 gram, Sodium hyaluronate 2.5 grams, taurine 1.3 grams, 0.9 gram of sodium chloride, boric acid 0.3 gram, disodiumedetate 0.4 gram, distillation 90 milliliters of water.
What described sodium hyaluronate used receives for powder clear matter acid, and powder mesh number is 1000 mesh.
The preparation method of a kind of Kanamycin sulfate eye drops, comprises the steps:
S1: prepare the test tube of two cleaning steriles, joined by kanamycin sulfate in test tube, falls the distilled water of half simultaneously Enter in test tube, firmly rock so that kanamycin sulfate is sufficiently mixed with distilled water, test tube is placed and water uses water-bath add The mode of heat heats, and bath temperature controls between 45-55 degree Celsius；
S2: by vitamin B6, sodium hyaluronate, taurine, sodium chloride, boric acid, disodiumedetate and second half steaming The test tube that distilled water is put in another test tube in mixing and stirring, with S1 heating in water bath in the same apparatus, it is ensured that two Test tube bath temperature is identical；
S3: solution in two test tubes is mixed, fully rocks so that solution mix homogeneously；
S4: sterilization treatment, uses the mode of high-temp steam sterilizing, is put into by mix reagent in high-temperature steam cabinet and carry out at sterilizing Reason；
S5: the solution through sterilization treatment is carried out filtration treatment, by Impurity removal, the drainage screen aperture of defecator is 1000 Mesh；
S6: by through filtration after solution subpackage in the vial, can use, subpackage in the vial time need bottleneck is gone out Bacterium processes.
Embodiment 3
A kind of Kanamycin sulfate eye drops, its raw material is as follows: kanamycin sulfate 6 grams, vitamin B6 0.5 gram, Sodium hyaluronate 3 grams, taurine 1.5 grams, 1 gram of sodium chloride, boric acid 0.4 gram, disodiumedetate 0.5 gram, distilled water 100 Milliliter.
What described sodium hyaluronate used receives for powder clear matter acid, and powder mesh number is 1000 mesh.
The preparation method of a kind of Kanamycin sulfate eye drops, comprises the steps:
S1: prepare the test tube of two cleaning steriles, joined by kanamycin sulfate in test tube, falls the distilled water of half simultaneously Enter in test tube, firmly rock so that kanamycin sulfate is sufficiently mixed with distilled water, test tube is placed and water uses water-bath add The mode of heat heats, and bath temperature controls between 45-55 degree Celsius；
S2: by vitamin B6, sodium hyaluronate, taurine, sodium chloride, boric acid, disodiumedetate and second half steaming The test tube that distilled water is put in another test tube in mixing and stirring, with S1 heating in water bath in the same apparatus, it is ensured that two Test tube bath temperature is identical；
S3: solution in two test tubes is mixed, fully rocks so that solution mix homogeneously；
S4: sterilization treatment, uses the mode of high-temp steam sterilizing, is put into by mix reagent in high-temperature steam cabinet and carry out at sterilizing Reason；
S5: the solution through sterilization treatment is carried out filtration treatment, by Impurity removal, the drainage screen aperture of defecator is 1000 Mesh；
S6: by through filtration after solution subpackage in the vial, can use, subpackage in the vial time need bottleneck is gone out Bacterium processes.
A kind of Kanamycin sulfate eye drops that the present invention provides and preparation method thereof, adding by kanamycin sulfate Enter, use the hybrid mode of branch's formula plurality of raw materials to be mixed simultaneously so that mixed effect is more preferably applicable to treat sensitive large intestine Conjunctivitis, keratitis, tear caused by the antibacterials such as angstrom uncommon bacterium, Klebsiella, Proteus, Diplococcus gonorrhoeae and staphylococcus Capsulitis, blepharitis, meibomitis etc. infect.
The above, the only present invention preferably detailed description of the invention, but protection scope of the present invention is not limited thereto, Any those familiar with the art in the technical scope that the invention discloses, according to technical scheme and Inventive concept equivalent or change in addition, all should contain within protection scope of the present invention.

Claims (3)

1. a Kanamycin sulfate eye drops, it is characterised in that: its raw material is as follows: kanamycin sulfate 4-6 gram, Vitamin B6 0.3-0.5 gram, sodium hyaluronate 2-3 gram, taurine 1-1.5 gram, 0.8-1 gram of sodium chloride, boric acid 0.2-0.4 gram, Disodiumedetate 0.3-0.5 gram, distilled water 80-100 milliliter.
A kind of Kanamycin sulfate eye drops the most according to claim 1, it is characterised in that: described sodium hyaluronate uses Receive for powder clear matter acid, and powder mesh number is 1000 mesh.
3. the preparation method of the Kanamycin sulfate eye drops described in a claim 1, it is characterised in that: include walking as follows Rapid:
S1: prepare the test tube of two cleaning steriles, joined by kanamycin sulfate in test tube, falls the distilled water of half simultaneously Enter in test tube, firmly rock so that kanamycin sulfate is sufficiently mixed with distilled water, test tube is placed and water uses water-bath add The mode of heat heats, and bath temperature controls between 45-55 degree Celsius；
S2: by vitamin B6, sodium hyaluronate, taurine, sodium chloride, boric acid, disodiumedetate and second half steaming The test tube that distilled water is put in another test tube in mixing and stirring, with S1 heating in water bath in the same apparatus, it is ensured that two Test tube bath temperature is identical；
S3: solution in two test tubes is mixed, fully rocks so that solution mix homogeneously；
S4: sterilization treatment, uses the mode of high-temp steam sterilizing, is put into by mix reagent in high-temperature steam cabinet and carry out at sterilizing Reason；
S5: the solution through sterilization treatment is carried out filtration treatment, by Impurity removal, the drainage screen aperture of defecator is 1000 Mesh；
S6: by through filtration after solution subpackage in the vial, can use, subpackage in the vial time need bottleneck is gone out Bacterium processes.
CN201610744774.4A 2016-08-29 2016-08-29 A kind of Kanamycin sulfate eye drops and preparation method thereof Pending CN106176806A (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
CN201610744774.4A CN106176806A (en) 2016-08-29 2016-08-29 A kind of Kanamycin sulfate eye drops and preparation method thereof

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CN201610744774.4A CN106176806A (en) 2016-08-29 2016-08-29 A kind of Kanamycin sulfate eye drops and preparation method thereof

Publications (1)

Publication Number Publication Date
CN106176806A true CN106176806A (en) 2016-12-07

Family

ID=57527229

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201610744774.4A Pending CN106176806A (en) 2016-08-29 2016-08-29 A kind of Kanamycin sulfate eye drops and preparation method thereof

Country Status (1)

Country Link
CN (1) CN106176806A (en)

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000228A1 (en) * 2000-06-29 2002-01-03 Rohto Pharmaceutical Co., Ltd. Oxygen-containing ophthalmic composition
CN1899304A (en) * 2006-07-07 2007-01-24 中国科学院南海海洋研究所 Eye drops for cataract and its preparing method
CN101057860A (en) * 2007-05-30 2007-10-24 杨文龙 Eye drops and preparing method thereof
CN101461776A (en) * 2009-01-06 2009-06-24 河北科技大学 Sodium hyaluronate eye drops without bacteriostatic agent and preparation method thereof

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002000228A1 (en) * 2000-06-29 2002-01-03 Rohto Pharmaceutical Co., Ltd. Oxygen-containing ophthalmic composition
CN1899304A (en) * 2006-07-07 2007-01-24 中国科学院南海海洋研究所 Eye drops for cataract and its preparing method
CN101057860A (en) * 2007-05-30 2007-10-24 杨文龙 Eye drops and preparing method thereof
CN101461776A (en) * 2009-01-06 2009-06-24 河北科技大学 Sodium hyaluronate eye drops without bacteriostatic agent and preparation method thereof

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
王永午: "《现代儿科药物治疗学》", 30 September 1998, 人民军医出版社 *

Similar Documents

Publication Publication Date Title
Chitsaz et al. The role played by drug efflux pumps in bacterial multidrug resistance
Ponziani et al. Eubiotic properties of rifaximin: Disruption of the traditional concepts in gut microbiota modulation
Scheiring et al. Treatment and outcome of Shiga-toxin-associated hemolytic uremic syndrome (HUS)
Wollenberg et al. Propionibacterium-produced coproporphyrin III induces Staphylococcus aureus aggregation and biofilm formation
Mariani-Kurkdjian et al. Haemolytic-uraemic syndrome with bacteraemia caused by a new hybrid Escherichia coli pathotype
Rodrigues et al. Etiologia e sensibilidade bacteriana em infecções do tracto urinário
Nipič et al. Escherichia coli uropathogenic-specific protein, Usp, is a bacteriocin-like genotoxin
CN102875574A (en) Crystal form of ceftriaxone sodium and preparation method for crystal form
Coleman et al. Probiotics in the treatment of otitis media. The past, the present and the future
Soundararajan et al. K5 capsule and lipopolysaccharide are important in resistance to T4 phage attack in probiotic E. coli strain Nissle 1917
CN101836950A (en) Moxifloxacin hydrochloride glucose injection and preparation method and use thereof
CN106176806A (en) A kind of Kanamycin sulfate eye drops and preparation method thereof
Adams et al. Shigella sonnei and hemolytic uremic syndrome: A case report and literature review
CN104292225A (en) Preparation method and use of substituted o-aminobenzoic acid berberine salt
Nelson et al. Comparative efficacy of cephalexin and ampicillin for shigellosis and other types of acute diarrhea in infants and children
Konturek et al. Gut microbiome and psyche: paradigm shift in the concept of brain-gut axis
Maev et al. Effectiveness of mebeverine in patients with post-cholecystectomy gastrointestinal spasm: results of prospective observational program “odyssey”
Barigye et al. Prevalence and antimicrobial susceptibility of virulent and avirulent multidrug-resistant Escherichia coli isolated from diarrheic neonatal calves
Espay et al. Unique form of propriospinal myoclonus as a possible complication of an enteropathogenic toxin
Amran et al. Proposal for effective treatment of Shiga toxin-producing Escherichia coli infection in mice
CN103371968A (en) Tobramycin sulfate injection and process for preparing same
CN105732608A (en) Preparation method and medical application of floxacin berberine coupling compound
Shah et al. Role of fecal microbiota transplant in management of hepatic encephalopathy: Current trends and future directions
Cavallazzi et al. Using steroids in patients with community-acquired pneumonia at the university of Louisville Hospital: who, what, and when
González-Villarreal et al. Molecular mechanisms of multidrug resistance in clinically relevant enteropathogenic bacteria

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20161207